Immuneering Corporation Class A Common Stock Q3 2025 Earnings Recap

IMRX Q3 2025 November 13, 2025

Get alerts when IMRX reports next quarter

Immuneering Corporation delivered a compelling third quarter of 2025 highlighted by promising clinical results from its Phase 2a trial of atebimetinib in combination with FOLFIRINOX for pancreatic cancer patients.

Earnings Per Share Miss

$-0.38 vs $-0.37 est.

-2.7% surprise

Market Reaction

1-Day -2.57%

5-Day +8.01%

30-Day -1.51%

See IMRX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Reported significant overall survival improvements in first-line pancreatic cancer patients treated with atebimetinib and FOLFIRINOX, strengthening development pipeline.
A case study showcased a 71-year-old patient achieving a 100% reduction in liver lesions after five months of treatment, indicating strong efficacy and safety profile.
Company plans to share substantial data updates in 2026, with potential presence at major medical meetings.
Ongoing trials aim to enhance treatment options for pancreatic cancer, which remains a significant area of unmet medical need.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit IMRX on AllInvestView.